The Journal of Biochemistry · 2015 · 29 citations · 29 references
MedicineMedicinal ChemistryPharmacologyBiochemical PharmacologyCell SignalingMolecular PharmacologyCell CharacterizationEnzyme InhibitionCell-based Drug ScreeningCell-based Pharmacological AssaysCell-based Screening AssaysDrug ScreeningPubmed Search
Transcriptional co-activator with PSD-95/Dlg-A/ZO-1 (PDZ)-binding motif (TAZ) regulates in cell proliferation and differentiation. In mesenchymal stem cells it promotes osteogenesis and myogenesis, and suppresses adipogenesis. TAZ activators are expected to prevent osteoporosis, obesity and muscle atrophy. TAZ activation induces epithelial-mesenchymal transition, confers stemness to cancer cells and leads to poor clinical prognosis in cancer patients. In this point of view, TAZ inhibitors should contribute to cancer therapy. Thus, TAZ attracts attention as a two-faced drug target. We screened for TAZ modulators by using human lung cancer A549 cells expressing the fluorescent reporter. Through this assay, we obtained TAZ activator candidates. We unexpectedly found that ethacridine, a widely used antiseptic and abortifacient, enhances the interaction of TAZ and protein phosphatases and increases unphosphorylated and nuclear TAZ. Ethacridine inhibits adipogenesis in mesenchymal C3H10T1/2 cells through the activation of TAZ. This finding suggests that ethacridine is a bona fide TAZ activator and supports that our assay is useful to discover TAZ activators.
29
Yap1 Acts Downstream of α-Catenin to Control Epidermal Proliferation
Karin Schlegelmilch, Morvarid Mohseni, Oktay Kirak et al. · Cell · 2011 · 1.1K citations · Full text
TAZ, a Transcriptional Modulator of Mesenchymal Stem Cell Differentiation
Jeong‐Ho Hong, Eun Sook Hwang, Michael T. McManus et al. · Science · 2005 · 1K citations